Replimune just took a devastating blow on Friday: its shares plummeted 59% to $1.98 after the announcement of the FDA's outright refusal to approve its experimental treatment for advanced melanoma. A scenario no trader wants to live through. 📉
🔍 What's going on?
The FDA has ruled: the data provided by Replimune were not robust enough to justify approval of its drug candidate in combination with Opdivo (Bristol Myers Squibb). The regulator criticizes Replimune for relying primarily on a single-arm study, which makes it impossible to truly isolate the benefits of the treatment when working in combination.
This negative opinion virtually seals the fate of the project. CEO Sushil Patel didn't mince his words: the company will have no choice but to cut jobs and drastically reduce its US manufacturing operations. A very clear signal of the direction to come.
💡 Why does it matter?
For you who follow biotech, this event is a harsh but necessary reminder: a single regulatory decision can wipe out market capitalization in a matter of hours. Replimune has lost 51% since the start of the year, and this debacle adds another layer.
Beyond Replimune, this is a wake-up call for all small biotechs betting on drug combinations without solid data. The FDA remains intractable on standards of proof, especially when you're an SME with no financial cushion to cash in on such a setback.
📊 Our opinion
We're frankly bearish on Replimune in the short to medium term. Not only does the regulatory rejection close the door on this flagship product, but the announced downsizing will curb any value creation. At $1.98, the stock remains on shaky ground: bearish momentum is massive, and there's no positive catalyst in sight. Small holders hoping for a revitalization are going to have to brace themselves for further turbulence.
✅ To remember
- Down 59% in one session following FDA rejection.
- Insufficient data on single study to justify approval.
- Drastic reduction in operations and jobs announced.
- Share down 51% since start of 2026.
- No positive catalyst identified on the horizon.
What do you think?Did you see this rejection coming, or were you one of those who still believed in approval? Share your analysis.
🔎 Also to be read
To go further, find all our Equities analysis on ActuTrading Equities 📈
